MTOR and lymphangioleiomyomatosis: The proliferation of LAM cells is commonly thought to be related to the mutational inactivation of gene TSC1 or TSC2 and subsequently abnormal activation of mTOR signaling pathway—the target of rapamycin and its analogs which become the only drugs for LAM treatment currently.